EOLS — Evolus, Inc.

Summary of Evolus Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Global Net Revenue: $69 million, a 13% increase year-over-year, driven by strong demand for Jeuveau and early contributions from Evolysse.
• Jeuveau Revenue: $63.2 million; Evolysse Revenue: $5.7 million.
• Gross Margin: Reported at 66.5%, adjusted gross margin at 67.6%.
• Operating Expenses: GAAP operating expenses were $57.3 million, up from $55.5 million in Q2 2025; non-GAAP operating expenses were $49.7 million, down from $54 million in Q2.
• Non-GAAP Operating Loss: $3.1 million, improved from a loss of $6.7 million in Q3 2024.
• Cash Position: $43.5 million at the end of Q3, down from $61.7 million in Q2, primarily due to inventory purchases ahead of potential tariffs.

2. Strategic Updates and Business Highlights

• New CFO: Tatjana Mitchell has joined as CFO, emphasizing a focus on efficiency and long-term growth.
• Evolus Training Programs: Over 17,000 injectors trained in 2025, with a significant correlation between training and product adoption.
• Evolysse Launch: Strong start with over 4,000 trained customers; $15.5 million in revenue since launch.
• Consumer Loyalty Program: Grew to 1.3 million members, with a 34% increase in total redemptions year-over-year.
• Regulatory Milestone: PMA submitted for Evolysse Sculpt, with potential FDA approval expected in the second half of 2026.

3. Forward Guidance and Outlook

• 2025 Revenue Guidance: Reiterated total net revenue between $295 million and $305 million, representing 11% to 15% growth over 2024.
• Evolysse Contribution: Expected to be 10% to 12% of total revenue for 2025.
• Profitability Expectations: Anticipate achieving non-GAAP operating income of $5 million to $7 million in Q4 2025 and sustainable annual profitability beginning in 2026.

4. Bad News, Challenges, or Points of Concern

• Market Headwinds: The U.S. aesthetic market remains challenged, with consumer spending pressures affecting demand for injectables.
• Tariff Risks: Potential tariffs on pharmaceuticals are being monitored, with some impact already incorporated into financial outlooks.
• Inventory Management: Customers are managing inventory levels carefully, impacting order sizes and patterns.
• Competitive Pressures: The overall HA market is experiencing declines, and Evolus faces competition from established players like AbbVie and Galderma.

5. Notable Q&A Insights

• Evolysse Adoption: The importance of second training sessions for product adoption was highlighted, with significant increases in purchasing volume observed post-training.
• Market Sentiment: There are signs of stabilization in consumer sentiment, but challenges persist, particularly with middle-income consumers.
• Bundling Strategy: Evolus plans to bundle Jeuveau and Evolysse products to enhance market penetration, with initial positive feedback from customers.
• Promotional Activities: The company is actively engaging in promotional efforts, including a partnership with Allure magazine and the annual 11th-day promotion, to drive consumer interest.

Overall, Evolus demonstrated solid growth in Q3 2025, with strategic initiatives in training and consumer engagement laying a strong foundation for future profitability, despite facing market challenges and potential tariff impacts.